AstraZeneca Pharma gets approval to launch cancer drug in India
This is to inform you that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India, to import and distribute Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi), according to a stock exchange filing.
Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of ...
Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.
AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...
The company has received approval to import, sell, and distribute Durvalumab Solution for infusion (Imfinzi) from the ...
Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...
The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...
The company has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution ...
The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.
AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback